A bipartisan group of legislators are sponsoring a piece of emergency legislation intended to accelerate the distribution of the coronavirus vaccine in Virginia.
COLONEL CHRISTOPHER M GRUSSENDORF > United States Air Force Academy > Display af.mil - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from af.mil Daily Mail and Mail on Sunday newspapers.
Published Online: December 17, 2020. doi:10.1001/jama.2020.24865
Correction: This article was corrected online December 28, 2020, to change the percentage of excess deaths to 50%.
Corresponding Author: Steven H. Woolf, MD, MPH, Center on Society and Health, Department of Family Medicine and Population Health, Virginia Commonwealth University School of Medicine, 830 E Main St, Ste 5035, Richmond, VA 23298 (steven.woolf@vcuhealth.org).
Conflict of Interest Disclosures: None reported.
Funding/Support: Drs Woolf and Chapman received partial funding from grant UL1TR002649 from the National Center for Advancing Translational Sciences.
Role of the Funder/Sponsor: The National Center for Advancing Translational Sciences had no role in preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
E-Mail
What The Viewpoint Says: This Viewpoint uses Centers for Disease Control and Prevention data to compare the COVID-19 mortality rate in 2020 with prior leading causes of death (heart disease, cancer, lung disease and injury) to put into context the cost of the infection in loss of life in the United States.
Authors: Steven H. Woolf, M.D., M.P.H., of the Virginia Commonwealth University School of Medicine in Richmond, Virginia, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https:/
Researchers identify new immune cell that acts as major driver of breast cancer growth
Breast cancer is the most common cancer in women worldwide, but many immunotherapies have had limited success in treating aggressive forms of the disease. A deeper understanding of the immunobiology of breast cancer is critical to the success in harnessing immunotherapeutic approaches to improve breast cancer survival, said Paula Bos, Ph.D., member of the Cancer Biology research program at VCU Massey Cancer Center and assistant professor in the Department of Pathology at the VCU School of Medicine.
New research findings from Bos, published in
Cell Reports, identified a type of immune cell that acts as a major driver of breast cancer growth by preventing the accumulation of a specific protein that induces anti-tumor responses. This new knowledge could be utilized for the development of novel immunotherapeutic approaches to treat the disease.